Press releases and news
2022
Camurus’ Interim Report Second Quarter 2022
Solasia acquires episil oral liquid business from Camurus
Change in number of shares and votes in Camurus
Camurus appoints Jonas Duborn as Head of Compliance
Invitation to Camurus’ Capital Markets and R&D Day 6 September 2022
Camurus to present at Jefferies 2022 Healthcare Conference New York
Change in number of shares and votes in Camurus
Resolutions at the annual general meeting 2022 in Camurus
Camurus' Interim Report January-March 2022
Camurus Annual Report for 2021
Notice of annual general meeting 2022 in Camurus AB (publ)
2021 and 2020 Lipid Science Prize awarded to inventors of m-RNA and lipid nanoparticle technologies
Camurus’ Full Year Report 2021
Camurus announces dosing initiated in Phase 3 trial of weekly setmelanotide in patients with genetic obesity disorder
2021
Change in number of shares and votes in Camurus
Braeburn receives new Complete Response Letter for Brixadi in the US
The European Medicines Agency accepts application to extend the Buvidal indication to include treatment of chronic pain
Camurus announces dosing initiated in Phase 3 study of CAM2029 in patients with neuroendocrine tumors
Camurus’ Interim Report Third Quarter 2021
Camurus’ Nomination Committee appointed for the Annual General Meeting 2022
Get the latest news from Camurus
Subscribe to receive latest news from Camurus directly in your email inbox.